Published: Tue, April 17, 2018
Medicine | By Douglas Stevenson

Treatment combo improves lung cancer survival times, study finds

Treatment combo improves lung cancer survival times, study finds

"I only treat lung cancer and I've been doing that for about 20 years".

"Some families in China do not have decent or any ventilators to expel the cooking oil smoke which could lead to lung cancer even if they don't smoke", said Wang Xiujian, a member of the Chinese Anti-Cancer Association (CACA).

The utility of the Framework as a national resource is the inclusion of strategies, tools and resources to support health professionals, service providers and policy makers.

Immuno-chemotherapy combo extends lung cancer victim's survival period, says the latest comprehensive study. It's called immunotherapy. Doctors have been using Keytruda and Opdivo for several years treating lung cancer. The report shows that 3.8 million people were diagnosed with cancer each year and more than 2.2 million patients died. Similarly, the new drug known as checkpoint inhibitors allows the immune system of the patient in order to destroy the deadly cancerous cells.

But the benefits for Opdivo and Yervoy lasted less than two months on average. By killing some tumor cells, chemotherapy could pop open the bags, release the contents and help immune cells — unleashed by the checkpoint drugs — to identify their prey.

Two thirds were given immunotherapy drugs combined with chemotherapy while...

Gandhis study included 616 patients with advanced lung cancer, from medical centers in 16 countries.

Dr Roy Herbst, a lung cancer specialist at Yale Cancer Centre, who was not involved in the studies, said it could be the start of a fundamental change in treatment. The median overall survival was 11.3 months in those who did not receive immunotherapy, whereas survival in the immunotherapy group was longer and the median has not yet been reached.

The estimated survival at 12 months was 69.2 percent in the group that received immunotherapy, and 49.4 percent in those who did not.

Like this: